Janne Røsvik

Alzheimer disease blood biomarkers: considerations for population-level use

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

Barriers and facilitators to the access to and use of formal dementia care: findings of a focus group study with people with dementia, informal carers and health and social care professionals in eight European countries

Principal Component Analysis of the Norwegian Version of the Quality of Life in Late-Stage Dementia Scale